LianBios - ADR Peer Comparison

$0.30

$-630.85 (-99.95%)

As on 18-Apr-2024 09:30EDT

Market cap

$34 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

--

P/B Ratio

0.2

Div. Yield

96.2 %

Edit

	LianBios - ADR	Kinnate BiopharmaÂ Inc (KNTE)
Market cap ($ Mln)	34	125
Revenue ($ Mln)	--	--
Net Profit ($ Mln)	-87.98	-112.65
Net Margin (%)	--	-2,822.80
RoE (%)	-39.72	-58.86
Price to Earnings	--	--
Price-To-Book	0.15	0.79

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	LianBios - ADR	Kinnate BiopharmaÂ Inc (KNTE)
Operating Revenue	0.00	0.00
Cost of Revenue	1.24	0.80
Gross Profit	-1.00	-0.60
Operating Expenses	106.56	120.78
Operating Profit (EBIT)	-106.56	-120.98
Other Income	0.00	3.93
Profit before Tax	-87.11	-112.65
Provision for Tax	0.87	-1.91
Profit after Tax (Net Income)	-87.98	-110.94
Minority Interest	0.00	0.00
Consolidated Profit	-18.28	-64.86

Liabilities ($ Mln)

	LianBios - ADR	Kinnate BiopharmaÂ Inc (KNTE)
Shareholder's Funds	202.34	159.33
Minority Interest	0.00	0.00
Non-Current Liabilities	1.16	2.28
Current Liabilities	25.63	12.00
Total Liabilities	319.96	278.83

Assets ($ Mln)

	LianBios - ADR	Kinnate BiopharmaÂ Inc (KNTE)
Non-Current Assets	5.10	15.43
Current Assets	257.81	158.18
Total Assets	319.96	278.83
Total Debt*	2.84	3.18
Net Current Assets	232.18	146.18

Cashflow ($ Mln)

	LianBios - ADR	Kinnate BiopharmaÂ Inc (KNTE)
Cash From Operating Activities	-99.19	-89.03
Cash Flow from Investing Activities	--	-6.83
Cash from Financing Activities	1.71	1.16
Net Cash Inflow / Outflow	--	-94.70

Ratios

Profitability Ratios

	LianBios - ADR	Kinnate BiopharmaÂ Inc (KNTE)
ROCE (%)	-35.43	-41.68
ROE (%)	-39.72	-62.16
ROA (%)	-26.56	-46.07
EBIT Margin (%)	--	--
Net Margin (%)	--	-2,822.80
Cash Profit Margin (%)	--	--

Growth Ratios

	LianBios - ADR	Kinnate BiopharmaÂ Inc (KNTE)
Revenue Growth (%)	--	--
EBIT Growth (%)	9.44	-2.41
Net Profit Growth (%)	22.28	2.28
EPS Growth (%)	--	7.38
Book Value Growth (%)	--	-33.25

Valuation Ratios

	LianBios - ADR	Kinnate BiopharmaÂ Inc (KNTE)
Price / Earnings	--	-2.35
Price / Book Value	--	1.20
Dividend Yield (%)	--	--
EV/EBITDA	2.40	-0.60
Market Cap ($ Cr)	--	--

Solvency Ratios

	LianBios - ADR	Kinnate BiopharmaÂ Inc (KNTE)
Debt to Equity	0.00	0.00
Short term debt to equity ratio	0.01	0.01
Current Ratio	10.06	13.19
Quick Ratio	10.13	13.19
Interest Coverage	-5.03	-64.76

Operating Efficiency Ratios

	LianBios - ADR	Kinnate BiopharmaÂ Inc (KNTE)
Debtors to sales (%)	--	--
Asset Turnover	0.00	0.00
Receivable days	--	--
Inventory Days	-2,197.02	--
Payable days	851.33	1,849.83
Cash Conversion Cycle	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly